5 Revealing Analyst Questions From Veeva Systems's Q4 Earnings Call

Veeva Systems delivered a positive fourth quarter, with results that exceeded Wall Street’s expectations and drove a significant share price reaction. Key contributors to the quarter’s performance included strong demand for modernizing legacy systems, especially in safety and R&D, and continued expansion in the customer base, particularly among top 20 pharmaceutical companies. CEO Peter Gassner emphasized that most demand stemmed from the need for scalable, automated core systems rather than direct AI adoption, stating, “The goal there is automation…AI is not the only way you do automation.” Management also credited robust execution in services and successful migrations to Vault CRM as important growth levers.

Is now the time to buy VEEV?

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Veeva Systems’s Q4 Earnings Call

• Joseph Vruwink (Baird): Asked about AI’s influence on demand and whether customers are funding programs for AI readiness. CEO Peter Gassner replied that while some projects cite AI as a motivator, most demand is driven by the need to modernize core systems and improve automation.

• Saket Kalia (Barclays): Inquired about the role Veeva plays in AI adoption within life sciences compared to large language model (LLM) providers. Gassner described customers’ preference for Veeva’s integrated, scalable solutions over point solutions, emphasizing trust and reliability.

• Brian Peterson (Raymond James): Sought clarification on the difference between subscription growth and normalized billings, especially as growth shifts from mature to newer products. Van Wagener explained that changes in product mix and tough comparisons, especially in Crossix, impact billing growth but remain within expectations.

• Alexei Gogolev (JPMorgan): Queried the firmness of top 20 customer commitments to Vault CRM and the factors driving customer growth. Shawah expressed high confidence in the commitments, citing strong execution and live deployments, while Van Wagener attributed customer growth to success in targeting emerging biotechs.

• Stanislav Berenshteyn (Wells Fargo): Asked about the significance and ramp for the recent RTSM win and the broader potential for AI agents in safety. Gassner explained RTSM’s critical role and differentiated selling motion, and highlighted that AI agents in safety are focused on automating labor-intensive processes with demonstrable ROI.

Catalysts in Upcoming Quarters

Going forward, the StockStory team will closely watch (1) adoption rates and customer feedback on new AI agents across Veeva’s product portfolio, (2) the pace of migrations and cross-sell success in Vault CRM and R&D cloud products, and (3) traction in the CRO channel for study-by-study sales to biotechs. We will also monitor execution on safety and RTSM deployments, as well as any acceleration in customer wins among top 20 pharmaceutical companies.

Veeva Systems currently trades at $189.08, in line with $188.48 just before the earnings. In the wake of this quarter, is it a buy or sell?

High-Quality Stocks for All Market Conditions

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it's flagging for this month — FREE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return).